Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: GSK3-beta as a candidate therapeutic target in soft tissue sarcomas

Fig. 2

In vivo effect of GSK3β inhibitor 9-ING-41 in soft tissue sarcoma. IB115 liposarcoma cells were xenografted in NSG mice. Once tumors reached 100mm3 (day 17), mice were treated either with placebo (9 mice) or with two injections of 9-ING-41 at 70 mg/kg (orange arrow, 7 mice) or one injection of Doxorubicin at 1 mg/kg (blue arrow, 6 mice) or both drugs (6 mice). Tumor growth (A) and mice body weight (B) were monitored until day 38 and analyzed with GraphPad prism software using two-way ANOVA test and Bonferroni post-hoc test (***p < 0.001). Combination treatment of 9-ING-41 and doxorubicin reduces significantly tumors volume

Back to article page